Scandion Oncology – Q4 & year-end report 2022
Scandion Oncology (Scandion) today announces its Q4 & year-end report 2022. The following is taken from the report. Francois Martelet, CEO: “I am passionate about unlocking the potential of Scandion in drug resistance to the benefit of our many stakeholders, and – above all – the patients” Key Figures & Highlights TDKK Q4 2022 Q1-Q4 2022 Q4 2021 Q1-Q4 2021 Operating loss -15,387 -80,166 -14,553 -55,367 Net finance income/cost -300 -2,034 -261 -1,846 Loss before tax -15,687 -82,200 -14,814 -57,213 Net loss -76,700 -14,806 -51,705 -15,687 Total assets 89,401 89,401 116,219 116,219 Cash Position 77,605 77,605 105,710 105,710 Total equity 70,327 70,327 104,541 104,541 Equity ratio 79% 79% 90% 90% Earnings per share (EPS) -0.37 -1.87 -0.46 -1.61 Shares outstanding, ending 40,706,972 40,706,972 32,135,544 32,135,544 Highlights during Q4 2022 On October 10, Scandion initiates recruitment in part 3 of the CORIST phase II trial. The first of up to 36 patients has been enrolled in part 3 of the CORIST trial in accordance with the planned timeline On October 28, Scandion announce results of extraordinary general meeting, including adoption of authorization to issue shares both with and without pre-emptive rights for the Company’s existing shareholders, along with election of new board member, Nils Brünner On December 1, Scandion appoints Francois Martelet, M.D., as new Chief Executive Officer. Francois brings a wealth of highly relevant experiences to Scandion as an experienced and passionate business leader with the qualifications to successfully develop Scandion Highlights after the end of the period On January 18, Scandion appoints Jan Stenvang, Ph.D., Chief Scientific Officer and member of Executive Management. Jan is co-founder of Scandion Oncology and has more than 20 years of experience in cancer research On January 19, Scandion receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101. The patent would provide protection of the commercial solid form of SCO-101 until at least 2042 The Q4 & year-end report 2022 is available on the Company’s website: www.scandiononcology.com. Audiocast today, February 22 at 10:00 am CET Today at 10:00, Scandion Oncology’s executive management […]